Heterozygous TSC1/2 mutations have been causatively linked to hyperactivation of the mammalian target of rapamycin (mTOR) pathway, leading to the aberrant cell growth and proliferation characterizing benign tumors in LAM [133,134,135,136,137,138]. Here, TSC1 is linked to lymphangioleiomyomatosis.